Posted by Michael Wonder on 31 Jul 2023
FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer
31 July 2023 - Today, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA approved test, or microsatellite instability-high.
Efficacy was evaluated in RUBY, a randomised, multicenter, double-blind, placebo-controlled trial.
